Healthy adult subjects
Conditions
Interventions
Repeated oral administration of SK-5307 for 7 days.
(2 groups x 2 periods, open-label crossover method)
Sponsors
Asano Kenji
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Subjects aged 18 years or older but less than 40 years (at the time of informed consent) 2. Subjects whose BMI (weight (kg)/[height (m)]2) is between 18.5 and 25.0 (at the time of screening test) 3. Subjects considered eligible for this study based on the results of screening examination by the investigator or sub-investigator. 4. Subjects who have the capacity to consent and whose written consent has been obtained from the subject
Exclusion criteria
Exclusion criteria: 1. Subjects with current medical history. 2. Subjects with a history of liver disease, renal disease, cardiovascular disease, hematological disease, endocrine system disease, digestive system disease, respiratory system disease, psychiatric or cranial nerve disease (including epilepsy), infectious disease that the investigator or sub-investigator judges to affect the safety of the subject or the evaluation of the investigational drug. 3. Subjects with clinically abnormalities in the screening or rest on the day of admission of 12-lead electrocardiogram in period I. 4. Subjects with a complication or a history of drug dependence or alcohol dependence. 5. Subjects with a complication or a history of drug hypersensitivity. 6. Subjects with a complication or a history of food allergy. 7. Subjects who had an average of 20 grams or more of alcohol per day. 8. Subjects who used any drug or supplement within 2 weeks prior to hospitalization in period I. 9. Subjects who had food or beverages containing grapefruit (juice or pulp) within 3 days prior to prior to hospitalization in period I. 10. Subjects who had ingested food or beverages containing St. John's wort (St. John's wort) within 1 week prior to hospitalization in period I. 11. Subjects who have donated 400 mL whole blood within 12 weeks prior to hospitalization in the first stage, 200 mL whole blood within 4 weeks, or blood component(plasma component, platelet component) within 2 weeks. 12. Subjects who had a positive result for HIV antigen/antibody, HBs antigen, or HCV antibody, or a positive reaction to syphilis serology or urine drug test at screening. 13. Subjects with a positive for SARS-CoV-2 nucleic acid amplification test on the day of admission. 14. Subjects with symptoms of suspected COVID-19 (novel coronavirus infection). 15. Subject who is in the opinion of the investigator or sub-investigator, unsuitable in any other way to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety, Pharmacokinetics, Pharmacodynamics | — |
Contacts
Public ContactKenji Asano
Sanwa Kagaku Kenkyusho Co.,Ltd.
Outcome results
None listed